Stromal Therapeutics is developing antibodies against novel stromal cell targets acting locally on the immune system to treat chronic immune-mediated diseases.
Stromal Therapeutics has raised €481k across 1 funding round from 1 investor, most recently a round in Feb 2022. Based in Basel, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-02-21 | Other |
| €481k |
| BaseLaunch |
| View deal → |
